Skip to main content

Saturday, July 20:  All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.
Patients: click here for more information. Faculty/Staff: click here for information.



Peter Bleszynski, M.D








The Cardiology Division offers a wide range of research projects to our fellows. We have outstanding clinical research opportunities. We are the home to the world's most successful sudden death arrhythmia research group, the Heart Research Follow-up Program. This research team leads the MADIT series of trials and other leading clinical studies in devices which treat lethal arrhythmias and conduction system defects.

The Cardiology Division also offers basic research within the Aab Cardiovascular Research Institute (CVRI). A wide range of basic science projects are available at the CVRI, including research into vascular biology, heart failure, and ion channels. The CVRI also is home to the URMC Howard Hughes Medical Institute (HHMI) Med-into-Grad Graduate Program for translational biomedical research.

View our Division research pages.

Research Spotlight: Zaid Al Jebaje, M.B.Ch.B.Zaid Al Jebaje, M.B.Ch.B.

Outcomes and Complications of Cardiac Resynchronization Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices

May 3, 2022

The role of cardiac resynchronization therapy (CRT-D) in heart failure patients has been well established, so has the role of continuous-flow left ventricular assist device (CF-LVAD). But the effect of both therapies on clinical outcomes and complications in patients with CF-LVAD is currently not well understood.

The University of Rochester medical center is one of the largest LVAD implant centers in the nation and a leader in the field of electrophysiology devices. A recent study led by Dr. Zaid Al Jebaje showed that In CF-LVAD patients, CRT-D was not associated with improved survival. The study also showed that device-related complications were frequently observed in patients with CRT-D.

Our data suggest that continuing CRT-D therapy in CF-LVAD patients should be considered on an individual basis.” - Dr. Zaid Al Jebaje, M.B.Ch.B.

Dr. Al Jebaje is a 2022 University of Rochester Cardiovascular Disease Fellowship graduate who will be joining Henry Ford Health System in Detroit, MI. as an Interventional Cardiology Fellow. The abstract was presented at the Heart Rhythm Society annual meeting July-2021 and published in Heart Rhythm journal in August 2021, DOI: